Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
Special Dividend Data
The current last sale of $2.469 is 7.35% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 2.55||$ 19.0801|
|Low:||$ 2.43||$ 2.30|
Company Description (as filed with the SEC)
We are a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. We are developing Endoxifen with two routes of delivery: a topical formulation, applied like a lotion, for the treatment of a condition called mammographic breast density (or, MBD); and an oral formulation for breast cancer survivors who do not benefit from taking oral tamoxifen, a current FDA-approved standard of care. We are also developing our patented intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer. In 2017, we completed a Phase 1 clinical study of our proprietary oral and topical formulations of Endoxifen. ... More ...
Nasdaq Official Price
Jun. 22, 2018
Jun. 21, 2018